MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Cash Flow 2011-2025 | INFU
Annual Cash Flow InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
17.5 M | 18.3 M | 20.3 M | 13.9 M | 11.4 M | 7.72 M | 7.91 M | - | - | 7.46 M | 5.45 M | 6.75 M |
Depreciation & Amortization |
13.4 M | 14.6 M | 14 M | 12.3 M | 11.3 M | 6.96 M | 6.9 M | 5.36 M | 3.63 M | 5.42 M | 5.67 M | 6.39 M |
Accounts Payables |
8.34 M | 7.86 M | 6.78 M | 7.96 M | 7.09 M | 5.52 M | 5.32 M | 6.59 M | 5.22 M | 4.74 M | 2.14 M | 4 M |
Accounts Receivables |
16.9 M | 15.4 M | 14.7 M | 12.1 M | 9.59 M | 11.4 M | 11.6 M | 12.6 M | 10.3 M | 10.7 M | 8.51 M | 7.35 M |
Total Inventories |
4.82 M | 3.94 M | 3 M | 2.9 M | 2.25 M | 1.76 M | 2.17 M | 1.92 M | 1.76 M | 1.23 M | 1.34 M | 3.22 M |
All numbers in USD currency
Quarterly Cash Flow InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | 1.78 M | - | - | - | 377 K | - | - | - | -151 K | - | 13 M | - | 4.08 M | - | 14.6 M | - | 2.65 M | - | 12.7 M | 4.26 M | 557 K | - | 9.53 M | 4.32 M | 1.27 M | - | 8.21 M | 4.85 M | 1.05 M | - | 4.1 M | 1.23 M | -1.44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.63 M | - | 5.83 M | 2.27 M | -15 K | - | 3.7 M | 2.93 M | 2.12 M |
Depreciation & Amortization |
3.28 M | 3.34 M | 3.32 M | - | 3.14 M | 3.03 M | 2.9 M | - | 3.07 M | 3.09 M | 3.2 M | - | 3.44 M | 3.4 M | 3.42 M | - | 3.74 M | 3.66 M | 3.57 M | - | 3.56 M | 3.53 M | 3.4 M | - | 3.13 M | 3.02 M | 2.9 M | - | 100 K | 1.16 M | 1.19 M | - | 100 K | 1.39 M | 1.41 M | - | 958 K | 922 K | 912 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 100 K | 100 K | 100 K | - | 1.7 M | 1.6 M | 1.56 M |
Accounts Payables |
10 M | 9.32 M | 8.37 M | 9.85 M | 8.91 M | 9.94 M | 9.8 M | 8.01 M | 7.63 M | 5.48 M | 7.37 M | 8.34 M | 6.65 M | - | 8.24 M | 7.86 M | 6.7 M | 7.8 M | 6.55 M | 6.78 M | 6.78 M | 6.78 M | 6.78 M | 7.96 M | 7.96 M | 7.96 M | 7.96 M | 7.09 M | 7.09 M | 7.09 M | 7.09 M | 5.52 M | 5.52 M | 5.52 M | 5.52 M | 5.32 M | 5.32 M | 5.32 M | 5.32 M | 6.59 M | 6.59 M | 6.59 M | 6.59 M | 5.22 M | 5.22 M | 5.22 M | 5.22 M | 4.74 M | 4.74 M | 4.74 M | 4.74 M | 2.14 M | 2.14 M | 2.14 M | 2.14 M | 4 M | 4 M | 4 M | 4 M |
Accounts Receivables |
24.3 M | 24.5 M | 23.9 M | 21.2 M | 22.8 M | 21.3 M | 20.5 M | 19.8 M | 19.5 M | 18.9 M | 18.3 M | 16.9 M | 16.1 M | - | 16.4 M | 15.4 M | 15.8 M | 15.5 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 9.59 M | 9.59 M | 9.59 M | 9.59 M | 11.3 M | 11.4 M | 11.4 M | 11.4 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 8.51 M | 8.51 M | 8.51 M | 8.51 M | 7.35 M | 7.35 M | 7.35 M | 7.35 M |
Total Inventories |
5.59 M | 5.67 M | 6.1 M | 6.53 M | 6.7 M | 6.84 M | 6.25 M | 6.4 M | 6.09 M | 5.71 M | 5.64 M | 4.82 M | 4.86 M | - | 3.88 M | 3.94 M | 3.7 M | 3.72 M | 3.23 M | 3 M | 3 M | 3 M | 3 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.25 M | 2.25 M | 2.25 M | 2.25 M | 1.76 M | 1.76 M | 1.76 M | 1.76 M | 2.17 M | 2.17 M | 2.17 M | 2.17 M | 1.92 M | 1.92 M | 1.92 M | 1.92 M | 1.76 M | 1.76 M | 1.76 M | 1.76 M | 1.23 M | 1.23 M | 1.23 M | 1.23 M | 1.34 M | 1.34 M | 1.34 M | 1.34 M | 1.31 M | 3.22 M | 3.22 M | 3.22 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company InfuSystem Holdings , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Baxter International
BAX
|
$ 19.11 | 0.95 % | $ 9.75 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 196.12 | 0.23 % | $ 56.4 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 5.47 | 3.01 % | $ 110 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 175.8 | -1.49 % | $ 5.48 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.73 | 0.64 % | $ 31 M | USA |
 |
Repro Med Systems
KRMD
|
$ 6.48 | -0.61 % | $ 295 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 84.34 | 0.44 % | $ 1.89 B | USA |
 |
ICU Medical
ICUI
|
$ 146.98 | -0.35 % | $ 3.58 B | USA |
 |
Alcon
ALC
|
$ 80.17 | 0.06 % | $ 40.4 B |  Schweiz |
 |
Merit Medical Systems
MMSI
|
$ 87.39 | -0.27 % | $ 5.09 B | USA |
 |
AtriCure
ATRC
|
$ 40.55 | 0.02 % | $ 1.9 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
electroCore
ECOR
|
$ 4.86 | 1.25 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
$ 13.16 | - | $ 538 M | USA |
 |
The Cooper Companies
COO
|
$ 82.57 | -0.37 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 116.64 | 0.4 % | $ 5.65 B | USA |
 |
Masimo Corporation
MASI
|
$ 133.28 | -0.44 % | $ 7.1 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 80.01 | -0.44 % | $ 4.03 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 32.4 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 577.15 | -0.03 % | $ 205 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.43 | 2.53 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.18 | - | $ 22.2 M |  Israel |
 |
STERIS plc
STE
|
$ 255.68 | 0.11 % | $ 25.2 B | USA |
 |
Stereotaxis
STXS
|
$ 2.43 | -0.82 % | $ 196 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | -0.48 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
$ 5.23 | 12.23 % | $ 54.3 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.0 | 0.59 % | $ 3.79 B | USA |
 |
ResMed
RMD
|
$ 244.44 | -0.07 % | $ 35.7 B | USA |
 |
Pro-Dex
PDEX
|
$ 40.4 | -2.38 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.86 | 1.92 % | $ 714 M | USA |
 |
Utah Medical Products
UTMD
|
$ 56.29 | -1.14 % | $ 204 M | USA |
 |
Repligen Corporation
RGEN
|
$ 165.66 | -0.42 % | $ 9.23 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.22 | 1.26 % | $ 2.28 B | USA |
 |
BioLife Solutions
BLFS
|
$ 25.41 | -0.2 % | $ 1.17 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 23.63 | -1.25 % | $ 1.16 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.82 | 0.22 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 122.33 | 0.03 % | $ 5.73 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 276.66 | -0.3 % | $ 20.2 B | USA |